What Is AOD-9604?

AOD-9604 is a synthetic peptide consisting of amino acids 177-191 of human growth hormone, plus an added tyrosine residue for molecular stability. Developed at Monash University, this fragment was engineered to retain the fat-metabolizing activity of growth hormone while avoiding the hormonal side effects associated with full-length hGH.

The peptide received GRAS status from the FDA in 2014. In a therapeutic context, it is prescribed by physicians and prepared by licensed compounding pharmacies. Because AOD-9604 is not a one-size-fits-all medication, dosage must be individualized based on patient health status, body composition, and treatment goals.

Standard Dosage Ranges

The following ranges reflect protocols commonly used in clinical peptide therapy practice and are informed by available clinical trial data.

Starting Dose

Most physicians begin AOD-9604 therapy at the lower end of the dosing range to assess individual tolerance. A typical starting dose is 250 mcg (0.25 mg) administered once daily via subcutaneous injection. This conservative approach allows the body to adjust to the peptide and enables the prescribing physician to monitor for any adverse reactions before increasing the dose.

Therapeutic Dose

After an initial period of 1 to 2 weeks at the starting dose, many protocols increase to 300 mcg to 500 mcg per day. The specific dose within this range depends on body weight, metabolic health, treatment goals, and individual response.

In the Phase IIb clinical trial that evaluated AOD-9604 for obesity, doses of 1 mg per day were used, though current clinical practice often employs lower daily doses based on clinical experience and the goal of optimizing the benefit-to-risk ratio.

Dose by Therapeutic Goal

These ranges are general guidelines. Your prescribing physician will determine the most appropriate dose for your situation.

Timing and Administration

When to Inject

AOD-9604 is most commonly injected on an empty stomach, as food intake (particularly carbohydrates and fats) may interfere with the peptide's absorption and activity. The two most popular timing strategies are:

• Morning, before breakfast: Inject at least 20 to 30 minutes before eating. This aligns with the body's natural fasting state and allows the peptide to act during morning metabolic activity.
• Before bed: Inject at least 2 to 3 hours after the last meal. This approach takes advantage of overnight fasting and may complement natural nocturnal growth hormone release patterns.

Some practitioners recommend splitting the daily dose into two administrations (morning and evening), though once-daily dosing is more common in standard protocols.

Injection Method

AOD-9604 is administered via subcutaneous injection, meaning the needle is inserted into the fatty tissue just beneath the skin. Common injection sites include the lower abdomen (at least 2 inches from the navel), the outer thigh, and the back of the upper arm.

Rotating injection sites helps prevent localized irritation and tissue changes from repeated injections in the same area.

Reconstitution

AOD-9604 typically arrives as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before use. Standard reconstitution involves slowly adding the bacteriostatic water to the vial wall, allowing it to run down and dissolve the powder without vigorous shaking. Shaking can damage the peptide's molecular structure.

Your compounding pharmacy and prescribing physician will provide specific reconstitution instructions, including the exact volume of water to add for your prescribed concentration.

Cycling and Duration

Cycle Length

AOD-9604 protocols typically run for 8 to 12 weeks as an initial cycle. This timeframe allows sufficient time for the peptide's metabolic and tissue-level effects to become apparent while keeping within the bounds of available safety data.

Rest Periods

Many physicians recommend a rest period of 4 to 6 weeks between cycles. While AOD-9604 does not appear to suppress the body's natural growth hormone production or cause receptor desensitization in the way some compounds do, periodic breaks are considered best practice in peptide therapy. Rest periods allow the physician to reassess the patient's response and determine whether continued therapy is warranted.

Long-Term Use

Some patients continue AOD-9604 therapy over multiple cycles spanning several months. Long-term protocols should include periodic lab work and clinical evaluations. Because multi-year continuous use data is limited, ongoing monitoring is particularly important for patients on extended regimens.

Factors That Affect Optimal Dosage

Body Weight and Composition

Larger individuals may require doses at the higher end of the therapeutic range to achieve comparable plasma concentrations. Body fat percentage also matters, as subcutaneous injection pharmacokinetics can differ based on the thickness and vascularity of the injection site tissue.

Metabolic Health

Patients with metabolic syndrome, insulin resistance, or other metabolic conditions may respond differently to AOD-9604. Physicians may adjust dosing or select specific timing strategies based on metabolic health markers.

Concurrent Peptide or Medication Use

When AOD-9604 is used as part of a multi-peptide protocol, the dose may be adjusted to account for synergistic effects. For example, when combined with BPC-157 for tissue repair, a lower AOD-9604 dose may be sufficient. Patients on prescription medications should have their full medication list reviewed for potential interactions.

Individual Response

Peptide therapy responses are inherently individual. Some patients achieve meaningful results at 250 mcg daily, while others require 500 mcg. Physician monitoring and patient feedback are the most reliable tools for dose optimization.

Common Dosing Mistakes to Avoid

• Injecting after a meal: Food in the stomach, particularly carbohydrates, can blunt the peptide's effectiveness. Always inject on an empty stomach.
• Skipping days inconsistently: AOD-9604 works best with consistent daily administration. Missing doses frequently undermines the cumulative metabolic effects.
• Self-adjusting the dose: Increasing the dose without physician guidance does not necessarily improve results and may increase side effect risk.
• Improper storage: Reconstituted AOD-9604 should be stored in the refrigerator (2-8 degrees Celsius) and used within the timeframe specified by the pharmacy, typically 28 to 30 days.
• Shaking the vial: Vigorous shaking during reconstitution can denature the peptide. Gently swirl or roll the vial instead.

Safety Considerations

AOD-9604 has a well-documented safety profile at the doses described above. In clinical trials using doses up to 1 mg daily, adverse event rates were comparable to placebo. The most common side effects (mild injection site reactions and occasional headache) are typically transient.

That said, dosing should never be determined without professional medical input. Individual health conditions, medication interactions, and treatment goals all influence what constitutes a safe and effective dose. Self-dosing based on internet forums or non-medical advice carries unnecessary risk.

Individuals who are pregnant, breastfeeding, or being treated for active cancer should not use AOD-9604.

How Form Blends Can Help

Form Blends takes the guesswork out of AOD-9604 dosing. Every patient receives a personalized protocol based on their medical evaluation, health goals, and body composition. Physicians determine the appropriate starting dose, titration schedule, and cycle length for each individual.

Patients also receive clear reconstitution and injection instructions, along with ongoing access to their care team for questions about timing, technique, and dose adjustments. Follow-up consultations ensure the protocol remains optimized throughout the treatment cycle.

All peptides are sourced from licensed compounding pharmacies that meet strict purity and potency standards.